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Abstract In the circulation, most of the insulin-like growth
factors (IGFs) are bound to a ternary 150 kDa complex with
IGF-binding protein (IGFBP)-3 and the acid labile subunit. In
the current study, we identify transferrin (Tf) by mass spectrom-
etry, and immunoprecipitation as a component of a major IGF-
binding fraction separated from human plasma. IGF ligand
blotting, cross-linkage experiments and surface plasmon reso-
nance spectrometry have been used to demonstrate the capability
of Tf to bind IGFs specifically. In combination with Tf, IGFBP-3
showed a 5-fold higher affinity for IGF-II than IGFBP-3 alone.
The data suggest that Tf may play an important role in
regulating IGF/IGFBP-3 functions. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The insulin-like growth factors (IGF-I and IGF-II) form
complexes with six high-a⁄nity IGF-binding proteins
(IGFBPs) which modulate their activities [1]. IGFBP-3, a
V43/45-kDa glycoprotein, is most abundant in serum and
sequesters both IGFs into ternary 150-kDa complexes with
the 85-kDa acid-labile subunit (ALS). The 150-kDa com-
plexes function as circulating reservoirs of IGFs, from which
they are released either by proteolysis of IGFBP-3 or inter-
action of the ternary complex with cell-associated glycosami-
noglycans [2]. Beside ALS, several other plasma proteins have
recently been reported to interact speci¢cally with IGFBP-3
and a¡ect its binding properties. A disintegrin and metallo-
protease-12 was found to bind and cleave IGFBP-3 in serum
[3]. Other plasma proteins of 70, 100, and 150 kDa bind to
IGFBP-3 [4] or form IGFBP-3-containing complexes with a
molecular mass above 200 kDa [5]. Furthermore, the inactive
protease precursor plasminogen, and ¢brin/¢brinogen bind to
the basic C-terminal region of IGFBP-3 [6,7].
In this study, we report the identi¢cation of transferrin (Tf)
as an IGFBP that was detected together with IGFBP-3 in a
plasma fraction puri¢ed by a⁄nity chromatography and re-
verse-phase high performance liquid chromatography (RP
HPLC). The surface plasmon resonance technique was used
to de¢ne the possible role of Tf in the IGF system.
2. Materials and methods
2.1. Reagents
IGF-I and IGF-II were purchased from GroPep, Adelaide, Austra-
lia. Glycosylated rhIGFBP-3 was kindly provided by Dr. A. Sommer
(Celtrix, Santa Clara, CA, USA). Tf and protein-A agarose came
from Sigma. Rabbit antiserum against rhIGFBP-3 was obtained
from UBI (Lake Placid, NY, USA) and the polyclonal antibody
against human Tf came from DAKO (Hamburg, Germany). IGF-I
and IGF-II were iodinated by the chloramine T-method [8].
2.2. Puri¢cation and identi¢cation of new serum IGFBPs
Cohn fraction IV of human plasma was fractionated as described
previously [9]. In brief, the puri¢cation scheme comprised the follow-
ing steps: (i) suspension of Cohn fraction IV in 2 M acetic acid, pH
3.0, 0.075 M NaCl; (ii) removal of IGF-I and IGF-II with SP-Sepha-
dex C-25 using a batch procedure; (iii) a⁄nity chromatography over
an IGF-II Sepharose 4B column at neutral pH and desorption of
bound proteins with 0.5 M ammonium acetate, pH 2.8; (iv) HPLC
chromatography over a Pro RPC 5/10 column (all chromatography
media from Pharmacia, Freiburg, Germany) in 0.1 tri£uoroacetic acid
with a gradient from 0 to 44% acetonitrile (ACN). Fractions of 0.5 ml
were collected and assayed for IGF-binding using a competitive bind-
ing protein assay [9] with [125I]IGF-I as tracer and for IGFBP-1, -2,
and -3 using speci¢c RIAs. The bulk of IGFBP-3 eluted at an ANC
concentration between 20 and 21.5%. The highest peak of IGF-bind-
ing appeared at 27.7% ACN. It was further analyzed by SDS^PAGE,
[125I]IGF-II ligand blotting [10], and silver staining. On Coomassie
blue-stained protein bands a ¢ngerprint analysis was performed:
cleavage by trypsin, extraction of the resulting peptides from the
gel, detection by mass spectrometry (Voyager-DE1 PRO, Applied
Biosystems, Foster City, CA, USA) and database search in Swiss-
Prot.010501 with the program MS-Fit/ProteinProspector (http://pro
spector.ucsf.edu). Proteins of the main HPLC fraction were labeled
with Na125I (Amersham Pharmacia Biotech, Freiburg, Germany) by
IODOGEN (Pierce, Rockford, IL, USA).
2.3. Cross-linkage analysis
100 ng of holo-Tf (Sigma) dissolved in 35 Wl of 20 mM NaPi bu¡er,
pH 7.0, containing 20 mM NaCl were incubated with [125I]IGF-I or
[125I]IGF-II (150 000 cpm) for 6^16 h at 4 C. Disuccinimidyl suberate
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(Pierce) in dimethyl sulfoxide was added to a ¢nal concentration of
0.5 mM and further incubated for 15 min on ice. The reaction was
stopped by addition of 5 Wl of 0.8 M Tris^HCl, pH 7.0, containing
8 mM EDTA. The samples were boiled in SDS-sample bu¡er and
analyzed by SDS^PAGE (10% acrylamide) and autoradiography.
2.4. Immunoprecipitation
Aliquots of the 125I-labeled 60-kDa fraction (100 000 cpm) in 60
mM Tris^HCl, pH 7.4, containing 0.15 M NaCl, 1% Triton X-100,
5 mM EDTA, 1 mM phenylmethylsulfonyl £uoride and 5 mM iodo-
acetic acid (bu¡er A), were incubated either with anti-human Tf or
IGFBP-3 antibodies for 3 h at 4‡C. The immunocomplexes were pre-
cipitated by protein-A agarose, washed three times in bu¡er A, solu-
bilized and analyzed by SDS^PAGE under non-reducing conditions.
2.5. Yeast two-hybrid analysis
The full length human IGF-II cDNA was kindly provided by Dr.
W. Rutter (San Francisco, CA, USA). The cDNAs encoding the
prepro-IGF-II form of aa 1^180 and the mature (m) IGF-II form
of aa 25^92 were ampli¢ed by PCR using primers IGF-II-F: 5P-GG-
AATTCCGGATGGGAATCCCAATGGGG-3P, IGF-II-R: 5P-CGG-
GATCCCGTCACTTCCGATTGCTGGC-3P, and mIGF-II-F: 5P-G-
GAATTCCGGGCTTACCGCCCCAGTGAG-3P, mIGF-II-R: 5P-C-
GGGATCCCGTCACTCGGACTTGGCGGGGGT-3P, respectively.
The PCR products were cleaved subsequently with EcoRI and BamHI
and subcloned in frame with the Gal4-DNA-binding domain of vector
pAS2-1 (Clontech). The human Tf cDNA (kindly provided by Dr. C.
Ko«rner, Go«ttingen, Germany) encoding aa 20^698 was ampli¢ed with
primers TRF-F: 5P-GAAGATCTTCGTCCCTGATAAAACTGTG-
3P and TRF-R: 5P-GAAGATCTTCTTAAGGTCTACGGAAAGT-
3P. PCR products were cleaved by BglII and cloned in frame with
the Gal4-activation domain (AD) into BamHI restriction sites of vec-
tor pACT2 (Clontech). The two-hybrid analysis was carried out as
described [11].
2.6. Surface plasmon resonance interaction analysis
Surface plasmon resonance interaction analysis was carried out as
described previously [10,12] using IGF-II-coupled CM5 sensor chips
in a BIAcore 2000 biosensor (Amersham Pharmacia Biotech, Frei-
burg, Germany). Because of the high a⁄nity of IGFBPs for IGF-II
and in order to minimize the in£uence of analyte re-binding during
the dissociation period, £ow rates ranging from 20 to 35 Wl/min were
used for all interaction measurements. The kinetic rate constants were
calculated exactly as described previously [12].
3. Results
Fractionation of human plasma Cohn fraction IV by a⁄n-
ity chromatography and subsequent RP HPLC yielded a ma-
jor IGF-binding component that contained only small
amounts of immunoreactive IGFBP-3, which could not ac-
count for the total IGF-binding capacity. Three major bind-
ing proteins of 100, 73, and a doublet of 45/43 kDa were
detected in this fraction by IGF-II ligand blotting (Fig. 1A).
The latter was identi¢ed as IGFBP-3 by immunoblotting (not
shown). Analysis of the proteins of this fraction by SDS^
PAGE and silver staining revealed three prominent bands at
100, 73, and 64 kDa (Fig. 1B). Fingerprint analysis identi¢ed
the 73-kDa protein as Tf. When the 125I-labeled proteins of
this fraction were incubated with antibodies against human
Tf, the 73-kDa component was immunoprecipitated (Fig. 2).
The precipitation of the 125I-labeled 73-kDa protein was in-
hibited by an excess of non-labeled Tf. Antibodies against
human IGFBP-3 precipitated four proteins of 45, 64, 80,
and 92 kDa from the 125I-labeled fraction (Fig. 2). The ab-
sence of the 125I-labeled 92-kDa protein in the starting mate-
rial and the reduction of intensities of the 45-, and 92-kDa
bands by the addition of unlabeled IGFBP-3 during precip-
itation suggest that the 125I-labeled 92-kDa protein represents
an IGFBP-3 dimer.
The capability of Tf to bind IGFs was tested with di¡erent
approaches. Cross-linking of [125I]IGF-I or -IGF-II incubated
with commercially available holo-Tf resulted in a labeled pro-
tein of approximately 80 kDa (Fig. 3A,B), which disappeared
in the presence of an excess of the respective unlabeled IGF.
Using the yeast two-hybrid system, no interaction between Tf
and the mature or prepro-IGF-II was detected (not shown),
indicating a low binding a⁄nity. To determine the precise rate
constants (ka, kd, and KD) for the interaction between Tf and
IGF-II, surface plasmon resonance spectroscopy was carried
out with IGF-II immobilized on a sensor surface. When Tf
was passed over the surface, a low-a⁄nity binding (KD = 831
nM) of Tf to IGF-II was measured. For comparison, under
the conditions used, a KD value of 4.4 nM was estimated for
the binding of IGFBP-3 to the IGF-II surface (Fig. 3C). Sur-
prisingly, the a⁄nity of IGFBP-3 in combination with Tf was
Fig. 1. IGF-II binding and protein composition of the serum frac-
tion isolated by RP HPLC (27% ACN). 2 Wg of the fraction were
separated on SDS^PAGE followed by [125I]IGF-II ligand blotting
(A), or visualized by silver staining (B). The position of the molecu-
lar mass marker and of Tf (U) identi¢ed by mass spectrometry are
indicated.
Fig. 2. Immunoprecipitation of Tf. Aliquots of the 125I-labeled ma-
jor IGF-binding fraction from RP HPLC (100 000 cpm) were either
directly solubilized (15 000 cpm; lane 1) or incubated with antibod-
ies against Tf (lanes 2 and 3) or IGFBP-3 (lane 4). As indicated, 10
Wg non-labeled Tf was added. The precipitated proteins were ana-
lyzed by SDS^PAGE and autoradiography. The positions of the
molecular mass marker proteins are indicated. (U) IGFBP-3; (6)
IGFBP-3 dimer.
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approximately ¢ve-fold higher for IGF-II (KD = 0.8 nM) than
for IGFBP-3 alone.
4. Discussion
Fractionation of human plasma Cohn fraction IV by the
described procedure revealed the presence of various IGFBPs
whose binding activities could not explained by the presence
of immunoreactive classical IGFBPs. Tf was identi¢ed as a
major component in the main IGF-binding fraction (eluted
from the RP HPLC column at 27% ACN). Whereas two other
proteins of 100 and 64 kDa in this fraction were also visual-
ized by silver staining, IGFBP-3 was only detected by immu-
no- or IGF ligand blotting. However, the IGF-II ligand blot
revealed that the 73- and 100-kDa but not the 64-kDa poly-
peptide bind IGF-II. The capability of Tf to bind IGF-I and
IGF-II was con¢rmed by cross-linking experiments. In the
course of the present study, Cohen and collaborators identi-
¢ed Tf as one of three proteins of 70, 100, and 150 kDa in
human serum which bind IGFBP-3 with high a⁄nity [4,13].
Whether the 100-kDa IGFBP-3-associated protein is also
identical with the 100-kDa IGFBP found in this study re-
mains to be examined. The two-hybrid system was used to
test the ability of Tf to bind IGF-II in yeast cells. Both co-
transformation of the full length IGF-II cDNA fused to the
Gal4-BD and the mature IGF-II fusion gene together with the
Tf^Gal4-AD fusion gene failed to show any interactions.
These data suggest a low binding a⁄nity between the two
polypeptides. Indeed, biosensor kinetic data revealed that
the a⁄nity of Tf for IGF-II was approximately 200-fold lower
than that of IGFBP-3. It should be noted, that Wong et al.
[14] using the same biosensor technique to measure the bind-
ing a⁄nity constants of IGFBP-3 to IGF-II, calculated a KD
value of 23 pM. This higher a⁄nity value is mainly due to
di¡erences in the dissociation rate with which IGFBP-3 elutes
from the sensor surface. In contrast to Wong et al., a three-
times higher £ow rate was used in the present study to min-
imize the e¡ect of re-binding of IGFBP-3 to the surface dur-
ing the dissociation period. Although there may be discrep-
ancies in the absolute kinetic rate constants under di¡erent
experimental conditions, the surface plasmon resonance mea-
surements are suitable for comparison of the interactions of
Tf and IGFBP-3 with IGF-II. Thus, Tf may be classi¢ed as a
new member of the IGFBP superfamily. However, except for
the presence of three of the ¢rst four conserved cysteine res-
idues occurring in the N-terminal domain of IGFBP-1 to -6 or
of the IGFBP related proteins, which have been shown to
have at least 100-fold lower a⁄nities for IGFs [15], no signi¢-
cant structural similarities were found in Tf. Furthermore, Tf
lacks conservation of the ‘GCGCCXXC’-motif. Therefore, Tf,
in addition to its function as the Fe3-carrier protein in serum
[16], appears to be unique in its ability to bind IGFs and to
interact with IGFBP-3. On the other hand, the physiological
role of Tf in the IGF/IGFBP system is still unclear. Beside the
fact that Tf is required for cell proliferation, survival and
di¡erentiation [17,18], it abolishes IGFBP-3-induced cell pro-
liferation and apoptosis in di¡erent cell lines [13]. On the
other hand, the Fe3^Tf complex might facilitate the trans-
port of IGFs across the capillary wall by receptor-mediated
transcytosis [19].
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